Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Danuglipron in Healthy Adults
NCT03309241Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity (3 cohorts), sponsored by Pfizer. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Oct 2017; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03309241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309241.